Literature DB >> 25537234

Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial.

Elena Lopez-Gonzalez1, Maria T Herdeiro, María Piñeiro-Lamas, Adolfo Figueiras.   

Abstract

BACKGROUND: The yellow-card scheme continues to be one of the principal methods for signal generation in pharmacovigilance. Nevertheless, under-reporting, one of its disadvantages, delays alert signals and has a negative influence on public health. Educational interventions in pharmacovigilance may have a positive impact on the spontaneous reporting of adverse drug reactions (ADRs).
OBJECTIVES: To assess the duration of the effect and effectiveness of an educational intervention in pharmacovigilance designed to improve ADR reporting in a robust pharmacovigilance system.
METHODS: A spatial, cluster randomized controlled trial was conducted covering all National Health System physicians in the northwest of Spain and targeting those who were actively engaged in clinical practice (n = 7,498). Of these, 2,120 were assigned in three spatial clusters to the intervention group (six hospitals and 138 primary care centers) and 3,614 in four clusters to the control group (seven hospitals and 267 primary care centers). The educational intervention consisted of two complementary approaches--one active (group sessions), the other passive (educational material, reporting form)-implemented from November 2007 to December 2008, with a follow-up period of 8 months.
RESULTS: Intervention participation was 53.7 % in a hospital setting and 60.5 % in primary care settings. ADR reporting in the intervention group increased by 65.4 % (95 % confidence interval [CI]: 8.2-153.4) across the follow-up. The ADR reporting rate per 1,000 physicians/year in the intervention group rose from 28.1 to 39.6 following the intervention (51.7 and 27.4 in the first and second 4-month period, respectively). For the intervention group, relative risk (RR) was 2.31 (95 % CI: 1.46-3.68) and 1.04 (95 % CI: 0.61-1.77) in the first and second 4-month period, respectively adjusted to baseline values. There was an increase in unexpected ADR reporting (RR 2.06, 95 % CI 1.19-3.55).
CONCLUSIONS: Pharmacovigilance educational interventions that have proved effective can be successfully applied in different geographical areas. A high baseline notification rate could account for the educational program having a moderate effect.

Mesh:

Year:  2015        PMID: 25537234     DOI: 10.1007/s40264-014-0256-6

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  21 in total

1.  A novel scheme for the reporting of adverse drug reactions.

Authors:  A Clarkson; E Ingleby; I Choonara; P Bryan; P Arlett
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

Review 2.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

3.  Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).

Authors:  Chiara Biagi; Nicola Montanaro; Elena Buccellato; Giuseppe Roberto; Alberto Vaccheri; Domenico Motola
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

4.  Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal.

Authors:  Maria Teresa Herdeiro; Inês Ribeiro-Vaz; Mónica Ferreira; Jorge Polónia; Amílcar Falcão; Adolfo Figueiras
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

5.  Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial.

Authors:  Adolfo Figueiras; Maria T Herdeiro; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  JAMA       Date:  2006-09-06       Impact factor: 56.272

Review 7.  Determinants of under-reporting of adverse drug reactions: a systematic review.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain.

Authors:  Consuelo Pedrós; Antoni Vallano; Gloria Cereza; Gemma Mendoza-Aran; Antònia Agustí; Cristina Aguilera; Immaculada Danés; Xavier Vidal; Josep M Arnau
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Effectiveness of pharmacovigilance training of general practitioners: a retrospective cohort study in the Netherlands comparing two methods.

Authors:  Roald Gerritsen; Hans Faddegon; Fred Dijkers; Kees van Grootheest; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

Review 10.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

View more
  18 in total

1.  Effect of Educational Interventions on Adverse Drug Reaction Reporting in a Cancer Institute in Japan: A Questionnaire Study.

Authors:  Masami Tsuchiya; Akihisa Esashi; Taku Obara; Kyoko Inooka; Nariyasu Mano; Chizuko Takamura
Journal:  Hosp Pharm       Date:  2018-04-13

Review 2.  Continuing education meetings and workshops: effects on professional practice and healthcare outcomes.

Authors:  Louise Forsetlund; Mary Ann O'Brien; Lisa Forsén; Liv Merete Reinar; Mbah P Okwen; Tanya Horsley; Christopher J Rose
Journal:  Cochrane Database Syst Rev       Date:  2021-09-15

3.  The development of a pharmacovigilance system in Bahrain.

Authors:  Zainab Abdulrasool
Journal:  Saudi Pharm J       Date:  2022-03-15       Impact factor: 4.562

4.  A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.

Authors:  Olga Morales Ríos; Luis Jasso Gutiérrez; Juan O Talavera; Martha María Téllez-Rojo; Víctor Olivar López; Juan Garduño Espinosa; Onofre Muñoz Hernández
Journal:  Int J Clin Pharm       Date:  2016-02

5.  A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia.

Authors:  Hisham Aljadhey; Mansour A Mahmoud; Thamir M Alshammari; Mohammed Al-Dhaeefi; Herve Le Louet; Susana Perez-Gutthann; Peter J Pitts
Journal:  Saudi Med J       Date:  2015-09       Impact factor: 1.484

6.  Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff.

Authors:  Fabiana Rossi Varallo; Cleopatra S Planeta; Patricia de Carvalho Mastroianni
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

7.  Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016.

Authors:  Ibrahim A Oreagba; Kazeem A Oshikoya; Comfort Ogar; Abiodun O Adefurin; Ali Ibrahim; Olufunsho Awodele; Yetunde Oni
Journal:  Pharmacol Res Perspect       Date:  2017-02-14

8.  Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.

Authors:  Preeti Singh; Manju Agrawal; Rajesh Hishikar; Usha Joshi; Basant Maheshwari; Ajay Halwai
Journal:  Indian J Pharmacol       Date:  2017 Nov-Dec       Impact factor: 1.200

Review 9.  Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2016-02-04       Impact factor: 8.775

10.  Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district.

Authors:  H M Haines; J C Meyer; R S Summers; B B Godman
Journal:  Eur J Clin Pharmacol       Date:  2020-04-15       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.